Valuation: Sernova Biotherapeutics Inc

Market Cap 37.76M 27.13M 23.5M 22.23M 20.12M 2.6B 38.05M 265M 102M 1.32B 102M 99.67M 4.21B P/E 2026 *
-4x
P/E 2027 * -3.33x
Enterprise Value 37.76M 27.13M 23.5M 22.23M 20.12M 2.6B 38.05M 265M 102M 1.32B 102M 99.67M 4.21B EV / Sales 2026 *
-
EV / Sales 2027 * 7.55x
Free-Float
89.49%
Yield 2026 *
-
Yield 2027 * -
1 day-9.09%
1 week-23.08%
Current month-9.09%
1 month-9.09%
3 months-35.48%
6 months-41.18%
Current year-23.08%
1 week 0.1
Extreme 0.095
0.15
1 month 0.1
Extreme 0.095
0.15
Current year 0.1
Extreme 0.095
0.2
1 year 0.1
Extreme 0.095
0.2
3 years 0.1
Extreme 0.095
0.83
5 years 0.1
Extreme 0.095
2.22
10 years 0.1
Extreme 0.095
2.87
Manager TitleAgeSince
Chief Executive Officer 58 2024-08-11
Director of Finance/CFO 60 2024-10-10
Investor Relations Contact - 2024-10-10
Director TitleAgeSince
Director/Board Member 60 2012-04-18
Director/Board Member - 2023-04-23
Director/Board Member - 2024-08-31
Date Insider Type Main position Quantity % Market Cap. Importance
7/3/26 SellCompany -115,000 0.0305%
5/22/26 Option

Chairman

228,912 0.0658%
5/22/26 Option

Director

260,000 0.0748%
Change 5-day change 1-year change 3-year change Capi.($)
-9.09%-23.08%-44.44%-87.34% 27.13M
-0.13%+1.83%-25.35%-3.85% 108B
-0.92%+1.12%-25.09%-2.54% 11.77B
+0.34%-7.22%+112.90%+128.54% 10.12B
-0.11%-5.11%-54.48%-71.65% 3.97B
-0.20%-4.44%-28.37%+23.21% 2.36B
+0.38%+20.05%-7.60%-64.63% 2.16B
-0.88%-5.48% - - 1.82B
+0.07%-4.17%-22.83%-30.97% 1.5B
Average -1.17%-2.68%-11.91%-13.65% 15.74B
Weighted average by Cap. -0.16%+1.08%-15.91%+3.13%

Financials

2026 *2027 *
Net sales - 5M 3.59M 3.11M 2.94M 2.66M 345M 5.04M 35.12M 13.51M 175M 13.5M 13.2M 557M
Net income -11.3M -8.12M -7.03M -6.65M -6.02M -779M -11.39M -79.36M -30.53M -395M -30.5M -29.82M -1.26B -13.9M -9.99M -8.65M -8.18M -7.41M -958M -14M -97.62M -37.56M -486M -37.52M -36.68M -1.55B
Net Debt - -
Logo Sernova Biotherapeutics Inc
Sernova Biotherapeutics Inc. is a Canada-based clinical-stage company, which is focused on developing regenerative medicine therapeutics combining its Cell Pouch with human donor cells or stem cell-derived cell therapies to create bio-hybrid organs to treat chronic diseases. A bio-hybrid organ is comprised of non-biomaterials, such as the Cell Pouch, integrated with living tissues to restore or enhance the function of a compromised organ. This approach aims to deliver a potentially revolutionary treatment for patients with chronic diseases, initially focusing on type 1 diabetes (T1D) and thyroid disorders. Cell Pouch is a bio-hybrid organ which is surgically implanted beneath the skin of the abdomen.
Employees
8
Date Price Change Volume
26-09-15 CA$0.1000 -9.09% 983,178
26-09-14 CA$0.1100 -18.52% 1,227,009
26-09-11 CA$0.1350 -3.57% 547,514
26-09-10 CA$0.1400 0.00% 500,864
26-09-09 CA$0.1400 +7.69% 350,479
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.1000CAD
Average target price
1.000CAD
Spread / Average Target
+900.00%

Quarterly revenue - Rate of surprise

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!